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Background
Chimeric antigen receptor (CAR) T cell therapy has
shown dramatic clinical success in CD19+ leukemia and
lymphoma patients. However, CAR T cell therapy for
epithelial cancers has been less successful. Developing
effective CAR T cell therapies for other types of cancer
may involve overcoming several obstacles associated
with solid tumors. Poor blood supply and dense stromal
components can hinder access of CAR T cells to tumor
cells. In addition, immunosuppressive elements in the
tumor microenvironment may suppress T cell functional
activity. Tumor associated macrophages (TAMs) have
been identified as key pro-tumor players in the microen-
vironment. Tumors co-opt macrophage function to help
promote tumor growth (“M2” polarization) via many
diverse mechanisms including promoting angiogenesis,
metastasis, and immune evasion. Indeed, the presence of
TAMs correlates with worse overall prognosis in many
types of cancer, including ovarian cancer patients. We
hypothesized that utilizing the power of CAR T cells to
target TAMs could be an effective way to improve CAR
T cell therapy in epithelial cancer.
Methods
Folate receptor beta (FRb), a GPI-linked membrane pro-
tein that mediates folic acid uptake, has previously been
described on TAMs in human cancer patients and
mouse models of cancer. We found that FRb is highly
expressed in monocyte-derived M2 polarized macro-
phages. Using high affinity human FRb-specific CAR
T cells (m923), we observed significant IFN-g secretion
and dose-dependent cytolysis of M2 polarized macro-
phages. When co-cultured with FRb(-) human ovarian
cancer cell line SKOV3, m923 CAR T cells mediated
bystander killing of FRb(-) tumor cells when FRb+ M2
polarized macrophages were present. Next, we con-
firmed high expression of FRb in TAMs from primary
ovarian cancer. m923 CAR T cells displayed specific
activation in the presence of primary ovarian cancer,
supporting the hypothesis that m923 CAR T cells could
be utilized to eliminate FRb+ TAMs in patients.
To test our hypothesis in preclinical mouse models,
we developed a mouse FRb-specific CAR (CL10).
Results
Using the implantable murine ovarian carcinoma ID8,
we confirmed expression of FRb in F4/80+/CD204+
TAMs isolated from peritoneal tumor ascites by flow
cytometry. In addition, CL10 CAR T cells displayed sig-
nificant specific reactivity against isolated CD11b+
TAMs. Our preliminary data suggest that adoptive
transfer of CL10 CAR T cells into ID8 tumor-bearing
mice results in destruction of FRb+ TAMs and delayed
tumor growth. Future experiments will determine
whether combining CL10 with tumor-directed CAR
T cells will result in synergistic anti-tumor effects.
Conclusions
In conclusion, our results suggest targeting TAMs with
CAR T cells may be a novel way to enhance CAR therapy
for solid tumors.
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